Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Freenome Lung Cancer Blood Test Receives FDA Breakthrough Device Status

13 August 2026 · By · Wire by Fusion42

Published

13 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at patientcareonline.com →

◆ Verified

Fusion42 · 13 August 2026 · Fusion42 review

Freenome's lung cancer blood test has received FDA Breakthrough Device designation, accelerating its development and review timeline in the United States.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 13 Aug 2026 and 14 Aug 2026.

◆ ◆ The Wire takeaway

Your biotech company must act fast to leverage the FDA's accelerated pathway for lung cancer diagnostics as regulatory clearance speeds up market entry opportunities.

◆ Coverage

2 sources · first reported 13 Aug 2026 · latest 14 Aug 2026

◆ Related on Wire

◆ Topics

Biotechlung-cancerblood-testfda-designationcancer-diagnostics